https://www.selleckchem.com/pr....oducts/Tipifarnib(R1
The GEM + IRE group had a significantly longer OS from the time of diagnosis of LAPC (19.8 mo 9.3 mo, 0.0001) than the GEM alone group. The GEM + IRE group had a significantly longer PFS (8.3 mo 4.7 mo, 0.0001) than the GEM alone group. Tumor volume less than 37 cm and GEM plus concurrent IRE were identified as significant favorable factors for both the OS and PFS. Gemcitabine plus concurrent IRE is an effective treatment for patients with LAPC. Gemcitabine plus concurrent IRE is an effective treatment for patients
Like
Comment
Share
